Scientists at the National University of Singapore have created a tiny, swallowable device that can survive the harsh acidic environment of the stomach and deliver cancer-fighting drugs directly to stomach tumors. The platform, called an acid-resistant nanocage, is designed to transport therapeutic enzymes that are normally destroyed by stomach acid. Once the nanocage reaches a tumor site, it releases the enzymes, which then trigger a reaction that kills cancer cells while sparing healthy tissue. The research, led by the Yong Loo Lin School of Medicine, represents a potential breakthrough in treating gastric cancer, one of the most common and deadly cancers worldwide. Current treatments like chemotherapy often damage healthy cells and cause severe side effects. The nanocage approach aims to make therapy more precise. In early preclinical tests, the nanocage successfully delivered enzymes into the acidic stomach environment and activated them at tumor sites. The researchers say this method could eventually lead to a pill that patients can swallow, avoiding the need for injections. The study is still in its early stages, and more research is needed before human trials can begin. However, the results are promising and offer a new strategy for targeted gastric cancer therapy. If successful, it could improve outcomes for patients while reducing the harmful side effects of conventional treatments.